Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
Daniela K van SantenSara LodiPaul DietzeWijnand van den BoomKanna Hayashi PhDHuiru DongZishan CuiLisa MaherMatthew HickmanAnders BoydMaria PrinsPublished in: Addiction (Abingdon, England) (2023)
In the Netherlands, Canada and Australia, comprehensive needle and syringe program and opioid agonist therapy participation appears to substantially reduce HIV and hepatitis C acquisition compared with no or partial needle and syringe program/opioid agonist therapy participation. These findings from an emulated trial design reinforce the critical role of comprehensive access to harm reduction in optimizing infection prevention for people who inject drugs.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- chronic pain
- pain management
- quality improvement
- antiretroviral therapy
- ultrasound guided
- hiv infected
- hiv positive
- hiv testing
- physical activity
- hiv aids
- study protocol
- randomized controlled trial
- men who have sex with men
- stem cells
- mesenchymal stem cells
- south africa
- bone marrow